CASC3 and cancer: Both proteasome inhibitors (e.g. BTZ) and topoisomerase poisons (e.g. ETO, doxorubicin) are used clinically as therapeutic anti-cancer agents, sometimes in combination (Cowell and Austin, 2012; Dittus et al., 2018; Manasanch and Orlowski, 2017; Nitiss, 2009b; Palumbo et al., 2008; Thomas et al., 2017).